Detalhe da pesquisa
1.
A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults.
Lung
; 200(3): 315-323, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35670873
2.
Autonomic Dysfunction Linked to Inhibition of the Nav1.7 Sodium Channel.
Circulation
; 149(17): 1394-1396, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38648272
3.
Dose-dependent quantitative effects of acute fructose administration on hepatic de novo lipogenesis in healthy humans.
Am J Physiol Endocrinol Metab
; 315(1): E126-E132, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29558206
4.
Efavirenz modulation of sleep spindles and sleep spectral profile.
J Sleep Res
; 24(1): 66-73, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25113527
5.
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Cell Metab
; 7(1): 68-78, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18177726
6.
Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough.
Clin Pharmacol Drug Dev
; 11(9): 1054-1067, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35510785
7.
Experimental Medicine Study to Measure Immune Checkpoint Receptors PD-1 and GITR Turnover Rates In Vivo in Humans.
Clin Pharmacol Ther
; 109(6): 1575-1582, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33280089
8.
Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.
Xenobiotica
; 40(10): 691-700, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20722472
9.
Evaluation of Therapeutics for Severely Debilitating or Life-Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development.
Clin Pharmacol Ther
; 107(3): 514-520, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31608984
10.
Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles.
J Nucl Med
; 60(1): 107-114, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880509
11.
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
J Clin Pharmacol
; 48(4): 418-27, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18258750
12.
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
J Clin Pharmacol
; 48(6): 734-44, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18508950
13.
A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone.
Ther Adv Drug Saf
; 6(3): 86-97, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26240742
14.
A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design.
AAPS J
; 16(6): 1259-70, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25160589
15.
Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin.
Diabetes Ther
; 4(2): 431-42, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24163113
16.
Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
Adv Ther
; 25(11): 1175-90, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18989636